Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Noble Biomaterials
AddedFeb 15, 2024
UpdatedJun 18, 2026
Noble Biomaterials

Noble Biomaterials

Public

Noble: Innovating silver-based materials to protect, save, heal, and improve lives.

HQ
Scranton, PA, US
Founded
1997
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to innovate silver-based materials, Noble Biomaterials aims to protect, save, heal, and improve lives through its advanced material technologies. The company offers a range of products including Ionic+®, Circuitex®, and Noble D-Fense™, which serve various markets such as life and style, health and medical, electronics and industrial, and aerospace and defense. Noble Biomaterials focuses on integrating its intelligent materials into products that enhance safety, performance, and well-being.

Notable affiliated individuals include industry leaders and experts in material science and healthcare. The company has garnered significant investment from stakeholders interested in cutting-edge material technology. Key achievements include the widespread adoption of their products in critical sectors and regulatory approvals that underscore their commitment to quality and safety. Overall, Noble Biomaterials has made a substantial impact by providing innovative solutions that address complex challenges across multiple industries.

Noble Biomaterials - Quick Facts

When was Noble Biomaterials founded?

Noble Biomaterials was founded in 1997.

Where is Noble Biomaterials' headquarters located?

Noble Biomaterials' headquarters is located in Scranton, PA, US.

When was Noble Biomaterials' last funding round?

Noble Biomaterials' most recent funding round was for $25k (USD) in June 2020.

How much has Noble Biomaterials raised to-date?

As of Jun 23, 2020, Noble Biomaterials has raised a total of $8M (USD).

How many employees does Noble Biomaterials have?

Noble Biomaterials has 100 employees as of Feb 4, 2024.

Noble Biomaterials - Classification

Ownership
  • Public
Technology
  • Antimicrobial
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
  • Transactional
Customer
  • Consumers
  • Enterprise
Main Product
  • Antimicrobial Materials
  • Silver Materials
Tags
  • Healthtech
  • Materials
  • Materials Science
NAICS
  • 330000Manufacturing
SIC
  • 3900Miscellaneous Manufacturing Industries